Table 2 Over-expression of miR-630 restores sensitivity to lapatinib, neratinib and afatinib in cells with either acquired- or innate resistance to HER-targeting drugs
Drug | Drug Conc. | Cell line | Drug + NC mimic | Drug + miR-630 mimic | % Anti-proliferative benefit with miR-630 mimic | p-value |
|---|---|---|---|---|---|---|
Lapatinib | 3 μM | SKBR3-LR | 82.5 ± 1.4 | 69.5 ± 1.2 | 12.9 ± 1.4 | 0.011 |
Lapatinib | 5 μM | HCC1954-LR | 27.6 ± 6.3 | 17.8 ± 4.5 | 9.7 ± 2.3 | 0.026 |
Lapatinib | 6 μM | MDA-MB-453 | 19.0 ± 0.9 | 9.9 ± 0.9 | 9.1 ± 1.6 | 0.015 |
Neratinib | 0.5 μM | SKBR3-LR | 63.3 ± 1.9 | 56.3 ± 1.2 | 7.0 ± 1.0 | 0.019 |
Neratinib | 0.5 μM | HCC1954-LR | 26.3 ± 4.6 | 22.3 ± 4.7 | 3.9 ± 0.1 | 0.000 |
Neratinib | 0.5 μM | MDA-MB-453 | 45.3 ± 7.5 | 28.3 ± 3.0 | 17.0 ± 4.9 | 0.037 |
Afatinib | 0.5 μM | SKBR3-LR | 78.4 ± 1.5 | 70.4 ± 0.7 | 8.4 ± 1.4 | 0.031 |
Afatinib | 0.5 μM | HCC1954-LR | 30.5 ± 7.0 | 20.7 ± 6.5 | 9.8 ± 0.5 | 0.001 |
Afatinib | 0.5 μM | MDA-MB-453 | 50.6 ± 8.3 | 31.4 ± 10.4 | 19.2 ± 2.3 | 0.007 |